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To the Editor: We read with interest the results of the clinical
trial comparing biocompatible with standard solutions in
peritoneal dialysis.1 We believe that the authors’ claim of
noninferiority of biocompatible solutions compared to
standard solutions is not supported by their data. If the
difference in the mean of urea and creatinine clearance,
DnCrCl, between the two groups was 6.5 l per week and its
standard deviation was 6 l per week then its 95% confidence
interval was 18.42 to 5.42 l per week and the corresponding
figures in ml/min units were 1.87 ml/min (1.83 to
0.54 ml/min).2 As a result, a noninferiority hypothesis set
on the assumption that the difference is less than 1 ml/min
cannot be maintained as the lower limit of the 95%
confidence interval, 1.83 ml/min, is far lower than
1 ml/min.
We do not understand how the probabilities of actual
differences in DnCrCl or DUvol being greater than particular
figures were calculated, especially DnCrCl, highly incon-
sistent with its confidence interval. Standard, frequentist,
statistics can only calculate the probability that a test statistic
would be as extreme as or more extreme than observed if the
null hypotheses were true, the P-value. Alternatively, Bayesian
statistics can provide those probabilities,3 but no mention
was made of it in the article.
Further studies with larger sample sizes are needed also to
assess whether biocompatible solutions are indeed noninfer-
ior to standard solutions.
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I thank Dr Garcia-Lopez for asking me to clarify the
statistics I used in my article.
Existing publications (including his own1) suggest that
biocompatible peritoneal dialysis solutions would be super-
ior than standard. With this in mind, we wished to
determine if patients using biocompatible peritoneal dialysis
solutions would have a smaller decrement in nCrCl. We
decided to use a predefined cutoff that we felt was clinically
relevant, of 1 ml/min; that is inferiority of standard solutions
would be proven if DnCrClbiocom–DnCrClstand4þ 1 ml/min.
Dr Garcia Lopez has correctly calculated that the 95%
confidence interval for DnCrClbiocom–DnCrClstand was 1.83
to þ 0.54 ml/min. As þ 1 ml/min falls outside this range, we
could not demonstrate that standard solutions were inferior
(that is, we demonstrated noninferiority).
The difference between the expected DnCrCl (þ 1 ml/min)
and the observed DnCrCl (0.64 ml/min) was 1.64 ml/min.
The standard error was 0.6, therefore the observed DnCrCl
was42.7 s.e. outside the expected DnCrCl. The probability of
randomly selecting a group of normally distributed patients
who lie42.7 s.e. from the expected mean is B0.003.
We claimed that standard solutions are not inferior to
biocompatible (with regard to preserving residual renal
function in unselected incident peritoneal dialysis
patients). I therefore strongly refute any suggestions that
our claims are not supported by data.
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The long forgotten salt factor
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To the Editor: Davenport et al.1 were able to write an article
on hypertension control in dialysis patients of several
thousand words in length without mentioning the word salt.
This is curious given the wide publicity that an article by
Cook et al.2 on the highly significant benefit obtained with
5–6 g salt intake per day in reducing cardiovascular morbidity
and mortality in a ‘prehypertensive healthy population’. The
study, over a 10-year period, was randomized and controlled,
and involved several thousand individuals.2 This latter
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